Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (111-120 of 289) with videos related to

Pageof 29
Sort By:
Lung Cancer (Amsterdam, Netherlands)|February 10, 2026
Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trialsYating Wang, Zhuoxin Sun, Arthi Sridhar, et al.
Clinical and Translational Science|January 16, 2015
Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?M E Blair Holbein, Jelena P Berglund, Kevin Weatherwax, et al.
JAMA Oncology|January 27, 2018
Characteristics of Patients Using Patient Portals in OncologyKelvin Pho, Rong Lu, Samantha Gates, et al.
Clinical Chemistry|June 18, 2026
Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer ImmunotherapyMatthew Lee, Jeffrey A SoRelle, Arun Everest-Dass, et al.
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Immunotherapy Use in Patients With Lung Cancer and ComorbiditiesMitchell S von Itzstein, Amrit S Gonugunta, Helen G Mayo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 11, 2020
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLCThomas E Stinchcombe, Robert C Doebele, Xiaofei Wang, et al.
Cancer|December 13, 2006
Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxisDavid E Gerber, Jodi B Segal, Amandeep Salhotra, et al.
Contemporary Clinical Trials Communications|September 17, 2025
Design and refinement of a clinical trial staffing model within the evolving landscape of oncology clinical trialsEllen Siglinsky, Hannah Phan, Silviya Meletath, et al.
Journal of Biomedical Materials Research. Part A|September 3, 2011
A novel polymer gel for the delivery of local therapies to intracranial tumors: In vivo safety evaluationDavid E Gerber, Gary L Gallia, Betty M Tyler, et al.
Plos One|April 10, 2020
Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?Mitchell S von Itzstein, Arjun Gupta, Kemp H Kernstine, et al.
Pageof 29

Showing results (111-120 of 289) with videos related to

Sort By:
Pageof 29
Lung Cancer (Amsterdam, Netherlands)|February 10, 2026
Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trialsYating Wang, Zhuoxin Sun, Arthi Sridhar, et al.
Clinical and Translational Science|January 16, 2015
Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?M E Blair Holbein, Jelena P Berglund, Kevin Weatherwax, et al.
JAMA Oncology|January 27, 2018
Characteristics of Patients Using Patient Portals in OncologyKelvin Pho, Rong Lu, Samantha Gates, et al.
Clinical Chemistry|June 18, 2026
Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer ImmunotherapyMatthew Lee, Jeffrey A SoRelle, Arun Everest-Dass, et al.
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Immunotherapy Use in Patients With Lung Cancer and ComorbiditiesMitchell S von Itzstein, Amrit S Gonugunta, Helen G Mayo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 11, 2020
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLCThomas E Stinchcombe, Robert C Doebele, Xiaofei Wang, et al.
Cancer|December 13, 2006
Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxisDavid E Gerber, Jodi B Segal, Amandeep Salhotra, et al.
Contemporary Clinical Trials Communications|September 17, 2025
Design and refinement of a clinical trial staffing model within the evolving landscape of oncology clinical trialsEllen Siglinsky, Hannah Phan, Silviya Meletath, et al.
Journal of Biomedical Materials Research. Part A|September 3, 2011
A novel polymer gel for the delivery of local therapies to intracranial tumors: In vivo safety evaluationDavid E Gerber, Gary L Gallia, Betty M Tyler, et al.
Plos One|April 10, 2020
Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?Mitchell S von Itzstein, Arjun Gupta, Kemp H Kernstine, et al.
Pageof 29